PRION-1: Quinacrine for Human Prion Disease

• Status: Completed
• Trial end date: 2007-03-01
• Target enrollment: 0
• Participant gender: All

Summary

PRION-1 aims to assess the activity and safety of Quinacrine (Mepacrine hydrochloride) in human prion disease. It also aims to establish an appropriate framework for the clinical assessment of therapeutic options for human prion disease that can be refined or expanded in the future, as new agents become available.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical Research Council
• Treatments: Quinacrine

Criteria

Inclusion Criteria:

• Aged 12 years or more, diagnosed with any type of human prion disease.

Exclusion Criteria:

• In a coma, or in a pre-terminal phase of disease such that prolongation of the current quality of life would not be supported

• Known sensitivity to quinacrine

• Been taking any other putative anti-prion therapy for less than 8 weeks